Akzo sells OBS to US group

Gibson, Jane
March 2007
ICIS Chemical Business;3/19/2007, Vol. 2 Issue 58, p4
Trade Publication
The article reports that Akzo Nobel is to sell its Organon BioSciences (OBS) business to U.S. pharmaceutical group Schering-Plough and has dropped plans to issue an initial public offering (IPO). Analysts said that the sale was higher than expected with UBS claiming that it was € 3.2 billion more than it estimated. After the purchase, Organon's research and manufacturing facility in Oss, Netherlands, will be the center of Schering-Plough's global gynecology and fertility activities.


Related Articles

  • Akzo Nobel/Schering-Plough: good deal all round.  // PharmaWatch: Monthly Review;Apr2007, Vol. 6 Issue 4, p16 

    The article presents information on Akzo Nobel NV selling its healthcare business unit, Organon BioSciences NV, to Schering-Plough Corp. for $14 billion cash. It states that the deal allows Akzo Nobel to conduct acquisitions of its own as well as expansion into non-pharmaceutical markets. It...

  • Akzo Nobel to sell Organon. Liming, Keith Tan; Ovrebekk, Hilde // ICIS Chemical Business Americas;3/19/2007, Vol. 271 Issue 11, p14 

    The article discusses the plan of Akzo Nobel to sell its stake in Organon BioSciences (OBS) to pharmaceutical group Schering-Plough. The deal, which is estimated at $14.5 billion, is expected to be closed in the second quarter of 2007. The deal increases the price of Akzo stock by 16 percent....

  • Schering-Plough acquires Intervet.  // Veterinary Record: Journal of the British Veterinary Association;3/31/2007, Vol. 160 Issue 13, p421 

    The article reports that American drug company Schering-Plough has acquired Organon Biosciences, a subsidiary of Dutch firm Akzo Nobel, in March 2007. Organon's products include canine vaccines, dewormers, poultry vaccines and bovine biologicals. Schering's animal health division produces animal...

  • EUROPE IN BRIEF. Robinson, Simon // ICIS Chemical Business;9/18/2006, Vol. 1 Issue 35, p11 

    The article offers news briefs on the petrochemical industry in Europe. The oxxynova dimethyl terephthalate business of Degussa is being sold by the company to part of the capital investment firm Arques Group for € 22 million. Shareholders of Akzo Nobel have approved splitting the firm...

  • Akzo Nobel to IPO Organon. Sinclair, Neil // Chemical Market Reporter;8/21/2006, Vol. 270 Issue 6, p12 

    The article reports that Akzo Nobel, a coatings and health care group, will sell 20 to 30 percent of its Organon Biosciences unit through initial public offering (IPO) in 2007 on the Euronext exchange in Amsterdam, Netherlands. Selling of Organon unit comes after the company disclosed in...

  • Schering-Plough buys Organon.  // TCE: The Chemical Engineer;Apr2007, Issue 790, p6 

    This article reports on the acquisition of Organon Biosciences, a unit of Akzo Nobel, by U.S.-based pharmaceutical company Schering-Plough for €11 billion. It says that the deal put an end to Akzo's plans to list Organon on the stock market. Akzo Nobel chief executive officer Hans Wijers...

  • …but it won't rush into purchases. Jagger, Anna // ICIS Chemical Business;6/18/2007, Vol. 2 Issue 71, p44 

    The article reports on the decision of Akzo Nobel not to rush into purchases following its divestment of Organon BioSciences (OBS), according to CEO Hans Wijers. Wijers states that potential acquisition targets would need to fit strategically with the existing portfolio and create value for...

  • Akzo's Chemicals Enter a New Era. Young, Ian // Chemical Week;11/1/2006, Vol. 168 Issue 36, p16 

    The article reports on the decision of Azko Nobel to become a manufacturer of chemicals and coatings after the split-off of its pharmaceuticals business Organon BioSciences (OBS) according to Akzo CEO Hans Wijers. It says that the separation of OBS follows after the completion of a major...

  • Schering-Plough to buy Intervet in winning bid for Organon BioSciences.  // DVM: The Newsmagazine of Veterinary Medicine;Apr2007, Vol. 38 Issue 4, p36 

    The article reports on the plan of Schering-Plough Corp. to buy Organon BioSciences NV for $14.4 billion in Kenilworth, New Jersey. This acquisition is said to include Intervet Inc. of Akzo Nobel NV and is expected to close by the end of 2007. Fred Hassan, chairman and chief executive officer...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics